Pfizer aims to double stock to $50 by 2031 amid pipeline hopes despite recent setbacks.

Pfizer's stock has struggled due to declining COVID-19 drug revenues and upcoming generic competition, keeping its price near $25.62 with a modest 6.7% dividend yield. Despite this, analysts see potential upside driven by promising new drugs in obesity, oncology, and vaccines, with a 12-month price target around $32 and a longer-term goal of $50 by 2031. Achieving $50 requires successful commercialization of new treatments like Berobenatide and sustained growth in oncology, balanced against patent risks. The stock trades at a low forward P/E of about 8x, suggesting room for multiple expansion if the pipeline delivers.